Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Switch Criteria For Chronic Illnesses, Risk Factors Differ - DeLap

This article was originally published in The Tan Sheet

Executive Summary

Prescription drugs that treat risk factors, rather than a chronic illness, may not be ideally suited for Rx-to-OTC switches due to the danger of side effects, FDA's Robert DeLap, MD/PhD, suggested at the Drug Information Association annual meeting in San Diego June 12-13.

You may also be interested in...



Rx-To-OTC Switch Flips On With June Public Forum, July NDAC Meeting

The suitability of specific Rx drug classes - such as antihypertensive agents, osteoporosis treatments and oral contraceptives - for OTC use will be examined by FDA at a June 28-29 meeting in Gaithersburg, Md.

Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting

FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.

Healthcare "Rationing" Not Acceptable Reason For Denying Switches - FDAer

The practice of "rationing" a drug, or wanting to keep it out of the hands of the general public, is not an acceptable singular reason for disapproving a switch candidate, FDA Office of Drug Evaluation V Director Robert DeLap, MD/PhD, stated at a switch summit held by the Consumer Healthcare Products Association July 16 in Washington, D.C.

Related Content

Topics

UsernamePublicRestriction

Register

PS091358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel